Massachusetts Jury Awards $88 Million in Defective Hernia Mesh Case

Massachusetts Jury Awards $88 Million in Defective Hernia Mesh Case

Introduction

Federal Jury Awards $88 Million to Alabama Couple

A federal jury in Massachusetts awarded $88 million to Larry Patterson and his wife, Tammy Patterson, in a lawsuit involving a Covidien hernia mesh product. The verdict was returned on August 4, 2026, following a three-week trial in federal court in Boston. The case, Patterson v. Covidien Inc. et al., was the first case from the broader Covidien hernia mesh litigation to proceed to trial. The jury found that Covidien's unit failed to provide an adequate warning about the dangers associated with the mesh implanted in Patterson. The award included $77 million for Larry Patterson and $11 million for Tammy Patterson. The jury did not award punitive damages and did not find Covidien liable for fraud, according to Reuters. 

Hernia Mesh Implanted During 2017 Surgery

The lawsuit arose from a 2017 hernia repair operation in which Larry Patterson, an Alabama resident, received Symbotex Composite Mesh, manufactured by Covidien. According to federal court records, Patterson alleged that the Symbotex mesh adhered to his bowel and subsequently contributed to a bowel obstruction and recurrence of his hernia. These complications eventually required another operation in 2020. The federal court identified the case as Civil Action No. 22-cv-10153-PBS, which is part of MDL No. 22-md-03029-PBS, the multidistrict litigation involving Covidien hernia mesh products.

Dispute Over the Mesh's Protective Coating

A significant issue in the litigation concerned the protective collagen coating used on Symbotex mesh. The plaintiffs argued that the coating was intended to act as a barrier between the mesh and surrounding organs during the healing process. Patterson's attorneys contended that the coating did not remain effective for the period physicians had been led to expect and that doctors were not adequately warned about the potential consequences. Reuters reported that the plaintiffs' lawyers specifically argued that Covidien's change from bovine to porcine collagen affected the longevity of the protective coating. These statements represent the plaintiffs' arguments presented during the litigation and should not be interpreted as a finding that every Symbotex device is defective.

Alleged Complications and Additional Surgery

Patterson's lawsuit focused on the serious medical complications he experienced after the original hernia repair. According to his allegations, the mesh adhered to his bowel and contributed to a bowel obstruction and hernia recurrence, ultimately requiring additional surgery. Federal court records describe these allegations in the case proceedings. The plaintiffs argued that exposure of the underlying mesh after the protective coating deteriorated could allow the mesh to adhere to internal organs. The defense disputed the plaintiffs' interpretation of the medical evidence and argued that other factors could have contributed to Patterson's complications.

Jury Finds Inadequate Warning

The jury's principal finding reported after the trial was that Covidien failed to provide an adequate warning concerning the dangers associated with the mesh implanted in Patterson. The resulting compensatory award totaled $88 million. Larry Patterson received $77 million, while Tammy Patterson received $11 million on her claim. Reuters reported that the jury did not award punitive damages and did not find that Covidien had committed fraud. This distinction is important because the verdict was based on compensatory damages awarded to the plaintiffs rather than a separate punitive damages award against the manufacturer.

Medtronic Disputes the Claims

Medtronic, Covidien's parent company, disputed the allegations made by Patterson. The company has maintained that its hernia mesh products have been used safely and has challenged the claim that the device caused Patterson's medical complications. During the litigation, the defense argued that factors other than the mesh could have contributed to his bowel obstruction and other medical problems. Medtronic's position is significant when reporting the case because the $88 million verdict represents the jury's decision in the Patterson lawsuit and does not establish that all Covidien hernia mesh products are defective or that every patient who received such a product suffered an injury.

First Bellwether Trial in Covidien Litigation

The Patterson case has particular significance because it was the first Covidien hernia mesh bellwether case to reach a jury. Bellwether cases are selected from larger groups of related lawsuits and can provide the court and the parties with information about how evidence and legal claims may be evaluated at trial. The litigation has been centralized in the U.S. District Court for the District of Massachusetts under multidistrict litigation proceedings. Federal court documents describe the MDL as involving products liability claims concerning hernia mesh products manufactured by Covidien LP and Sofradim Production SAS.

Thousands of Other Claims Remain

The verdict comes amid a much larger group of lawsuits involving Covidien's hernia mesh products. Reuters reported that approximately 2,400 cases were consolidated in the federal MDL in Massachusetts, while Medtronic faces more than 10,000 similar cases nationwide. The broader litigation involves allegations concerning several hernia mesh products, including Symbotex, and claims relating to alleged injuries, product design and warnings. The Patterson case therefore represents only one lawsuit within a significantly larger body of litigation against Covidien and its related entities.

Verdict Does Not Automatically Determine Other Cases

The $88 million verdict does not automatically establish liability or damages in the other pending lawsuits. Each case may involve different circumstances, including the specific mesh product implanted, the patient's medical history, the type of surgery performed, the alleged injury and the evidence concerning causation and warnings. The Patterson verdict nevertheless gives the parties involved in the wider litigation an important jury decision involving Symbotex mesh. Future cases will continue to be evaluated according to their own evidence and individual circumstances rather than being automatically decided by the outcome of Patterson's lawsuit.

Broader Significance of the Verdict

The Patterson verdict has attracted attention because it represents the first jury decision in the Covidien hernia mesh multidistrict litigation. The case placed issues concerning product warnings, the design and performance of the mesh's protective coating, and the alleged medical consequences of the device before a federal jury. The award also provides an important data point for the thousands of other claims pending against Medtronic and its Covidien unit. However, the verdict applies specifically to Larry and Tammy Patterson and should not be interpreted as a determination that every patient implanted with Covidien hernia mesh will receive compensation or that every such product is legally defective. The individual facts and evidence in each lawsuit will remain central to determining its outcome.